A Bad Day for Lucentis
This article was originally published in RPM Report
Executive Summary
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
You may also be interested in...
Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.
Eylea Pricing is Eye-Opening: Regeneron Plays to CMS, Payors on Price; Docs with Terms
Choosing between doctors and payors in the “buy-and-bill” sector used to be easy – price to the doctor’s advantage. The higher the price, the larger the spread and the happier the drug company. Regeneron is bending that model towards the reimbursers (and Medicare, in particular) with Eylea. Regenero
Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?